Current News

Contact | Print version | PDF version | Send article | RSS-Feed

NextGen Sciences Appoints New CEO and Expands Service Offering to Include Protein Biomarker Monitoring

13 Nov 2007 - NextGen Sciences, provider of gene-to-protein products and services, has appointed Dr Mike Pisano as CEO, and has announced the expansion of its portfolio of services to include clinical protein biomarker monitoring.
 
Dr Pisano joins the Company from Proteomic Research Services (PRS), which was acquired by the NextGen Group in November 2006, where he was cofounder and CEO. With over a decade of senior management experience in the pharmaceutical industry, Dr Pisano's previous roles include Group Leader, Proteomics and Protein Production, Rhone-Poulenc Rorer Pharmaceuticals; Head, Protein Sciences, Aventis Pharmaceuticals; and Vice-President Proteomic R&D, Genomic Solutions, Inc. Dr. Pisano currently serves on the Scientific Advisory Board of several life sciences companies and instrumentation manufacturers.
 
The new protein biomarker services from NextGen Sciences include assay development and validation, monitoring and verification of protein biomarkers from pre-clinical and clinical samples, and identification of putative protein biomarkers and proteins of interest.